Kala Pharmaceuticals touted data today from a Phase III trial of its nanoparticle formulation of loteprednol etabonate as a treatment for inflammation and pain in cataract surgery patients. The KPI-121 1% suspension met both primary efficacy endpoints and secondary endpoints and was well tolerated by the trial’s participants.
The Waltham, Mass.-based company’s KPI-121 uses Kala’s mucus-penetrating particle technology to deliver drugs to tissues in the eye. In preclinical studies, MPP tech increased loteprednol etabonate delivery to ocular tissues 4-fold, according to the company.
Get the full story at our sister site, Drug Delivery Business News.
The post Kala touts Phase III data for nanoparticle ophthalmic suspension appeared first on MassDevice.